Page 28 - Nsclc News Today

Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.

When is stage III NSCLC resectable? Experts attempted to reach a consensus on when to perform surgery.

AEGEAN is one of the first studies of immune checkpoint inhibitors in the perioperative settings to demonstrate improved EFS and pCR with no effect on surgical outcomes.

Antibody-drug conjugates link a tumor-targeted antibody to a cytotoxic drug through a chemical linker and hold the promise of high potency.

The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.

Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.

Lung cancers, particularly those with T1 disease, could be reclassified into a different overall stage if proposed adaptations to the N and M categories of the TNM classification are adopted.

The addition of atezolizumab to bevacizumab, carboplatin, and pemetrexed or paclitaxel (ABCP) did not result in a statistically significant improvement in progression-free survival vs BCP for patients with metastatic nonsquamous non–small cell lung cancer in the first line, missing the primary end point of the phase 3 IMpower151 study.

While some types of lung cancer have targeted therapies, there remains a need for identification of biomarkers to predict treatment response in small cell lung cancer (SCLC).

Patients with advanced or metastatic non–small cell lung cancer (NSCLC) were able to specify a 1-point threshold when describing meaningful symptom change, for better or worse, that helped illustrate their symptom experience.